Business Services · Washington, United States · 50 Employees
TwinStrand Biosciences is leading the way in identifying ultra-low frequency genomic variants that are undetectable by conventional methods. The company's highly sensitive and specific Duplex Sequencing technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. This data can inform critical decisions in clinical medicine, public health, and other fields of science on a faster timescale, where actions are most impactful. TwinStrand's scientist-leaders have authored more than two dozen peer-reviewed articles using Duplex Sequencing Technology and have developed a portfolio of more than 100 patents and patent applications. The company has partnered with pharmaceutical companies, academic centers, clinical research networks and federal regulatory agencies to bring high precision genomics to the forefront of their science. The company was founded in 2015 out of Seattle, Washington.
View Company Info for Free
Who is TwinStrand Biosciences
Top Competitors of TwinStrand Biosciences
TwinStrand Biosciences Org Chart
Chief Scientific Officer
TwinStrand Biosciences Company Metrics
Total Funding Amount
Most Recent Funding Amount
Number of Funding Rounds
Top Companies in United States
TwinStrand Biosciences News & Media
- Duplex Sequencing can deliver 10,000x greater accuracy than standard NGS allowing for exquisitely sensitive mutation and genetic allele detection to inform critical medical decisions and drug development pipelinesExperienced Molecular Diagnostics
- SEATTLE--(BUSINESS WIRE)--TwinStrand Biosciences, Inc. (TwinStrand), the pioneer in Duplex Sequencing technology, which delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology, today announced that the company has implemented a reorganization designed to sustain growth through a focus on key commercial initiatives. As part of this effort, TwinStrand has named Chad Brown as interim Chief Executive Officer, while TwinStr
- The Seattle-based NGS sample preparation firm informed employees of the decision Monday, nearly a year and a half after it raised $50 million in Series B funding.
Singular Genomics and TwinStrand Biosciences Collaborate to Develop Ultra-high Accuracy NGS Solutions for the G4 PlatformThis partnership combines TwinStrand’s proven duplex sequencing solution with Singular’s HD-Seq™ technology on the G4 Sequencing Platform to maximize mutation detection sensitivities for applications such as monitoring measurable residual disease (MRD)SAN DIEGO, June 06, 2022 (GLOBE NEWSWIRE) -- Singular Genomics Systems Inc. (Nasdaq: OMIC) and TwinStrand Biosciences, Inc. today announced a collaboration to develop highly sensitive next generation sequencing (NGS) solutions for the Singular G4 S
TwinStrand Biosciences to Showcase Recent Applications of its Duplex Sequencing Technology at the 2022 AGBT Annual MeetingSEATTLE--(BUSINESS WIRE)-- #AGBT22--The company will present several data sets as part of its sponsorship and participation in the annual AGBT conference in Orlando.
Frequently Asked Questions regarding TwinStrand Biosciences
TwinStrand Biosciences is leading the way in identifying ultra-low frequency genomic variants that are undetectable by conventional methods. The company's highly sensitive and specific Duplex Sequencing technology delivers clearer insights to researchers and clinicians in applications ranging from residual cancer detection to genetic toxicology. Th...